| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Articles |
1
Departments of Pathology and
2
Medical and Research Technology, University of Maryland School of Medicine, Baltimore, MD 21201.
3
Department of Pathology and Laboratory Medicine,
Hartford Hospital, Hartford CT 06102.
4
University of Tennessee Medical Center at Knoxville,
Dynacare-Tennessee, Knoxville, TN 37920.
5
Department of Laboratory Medicine and Pathology,
Hennepin County Medical Center and University of Minnesota School of
Medicine, Minneapolis, MN 55415.
6
Ischemia Technologies, Denver, CO 80221.
a Address correspondence to this author at: Clinical Pathology, University of Maryland Medical Center, 22 South Greene St., Baltimore, MD 21201. Fax 410-328-5880; e-mail
rchriste{at}umaryland.edu.
Background: The ability of the N-terminal region of human albumin to bind cobalt is diminished by myocardial ischemia. The characteristics of an assay based on albumin cobalt binding were assessed in suspected acute coronary syndrome patients and in a control reference population. The ability of the Albumin Cobalt Binding (ACBTM) Test measurement at presentation to predict troponin-positive or -negative results 6–24 h later was also examined.
Methods: We enrolled 256 acute coronary syndrome patients at four medical centers. Blood specimens were collected at presentation and then 6–24 h later. The dichotomous decision limit and performance characteristics of the ACB Test for predicting troponin-positive or -negative status 6 h-24 h later were determined using ROC curve analysis. Results for 32 patients could not be used because the time of onset of ischemia appeared to have been >3 h before presentation or was uncertain. The reference interval was determined by parametric analysis to estimate the upper 95th percentile of a reference population (n = 109) of ostensibly healthy individuals.
Results: Increased cTnI was found in 35 of 224 patients. The ROC curve area for the ACB Test was 0.78 [95% confidence interval (CI), 0.70–0.86]. At the optimum decision point of 75 units/mL, the sensitivity and specificity of the ACB Test were 83% (95% CI, 66–93%) and 69% (95% CI, 62–76%). The negative predictive value was 96% (95% CI, 91–98%), and the positive predictive value was 33% (95% CI, 24–44%). The within-run CV of the ACB Test was 7.3%. Results for the reference population were normally distributed; the one-sided parametric 95th percentile was 80.2 units/mL.
Conclusions: This exploratory study suggests that the ACB Test has high negative predictive value and sensitivity in the presentation sample for predicting troponin-negative or -positive results 6–24 h later.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  A F Manini, J Ilgen, V E Noble, F Bamberg, W Koenig, J S Bohan, and U Hoffmann Derivation and validation of a sensitive IMA cutpoint to predict cardiac events in patients with chest pain Emerg. Med. J., November 1, 2009; 26(11): 791 - 796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Sbarouni, P. Georgiadou, M. Koutelou, I. Sklavainas, D. Panagiotakos, and V. Voudris Ischaemia-modified albumin in dilated cardiomyopathy Ann Clin Biochem, May 1, 2009; 46(3): 241 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. V. G. Edwards, M. Y. White, and S. J. Cordwell The Role of Proteomics in Clinical Cardiovascular Biomarker Discovery Mol. Cell. Proteomics, October 1, 2008; 7(10): 1824 - 1837. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P O Collinson and D C Gaze Ischaemia-modified albumin: clinical utility and pitfalls in measurement J. Clin. Pathol., September 1, 2008; 61(9): 1025 - 1028. [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Talwalkar, M. Bon-Homme, J. J. Miller, and R. J. Elin Ischemia Modified Albumin, a Marker of Acute Ischemic Events: A Pilot Study Ann. Clin. Lab. Sci., January 1, 2008; 38(2): 132 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, and R. H. Christenson National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes Circulation, April 3, 2007; 115(13): e356 - e375. [Full Text] [PDF]
|
|
|
|
 |
|
 NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, R. H. Christenson, NACB COMMITTEE MEMBERS, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes Clin. Chem., April 1, 2007; 53(4): 552 - 574. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Sbarouni, P. Georgiadou, D. Panagiotakos, E. G. Livanis, G. N. Theodorakis, and D. Th. Kremastinos Ischaemia modified albumin in radiofrequency catheter ablation Europace, February 1, 2007; 9(2): 127 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Sbarouni, P. Georgiadou, G. N. Theodorakis, and D. Th. Kremastinos Ischemia-Modified Albumin in Relation to Exercise Stress Testing J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2482 - 2484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Can, S Demirtas, O Polat, and A Yildiz Evaluation of effects of ischaemia on the albumin cobalt binding (ACB) assay in patients exposed to trauma. Emerg. Med. J., July 1, 2006; 23(7): 537 - 539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Middleton, R. Shave, K. George, G. Whyte, J. Forster, D. Oxborough, D. Gaze, and P. Collinson Novel application of flow propagation velocity and ischaemia-modified albumin in analysis of postexercise cardiac function in man Exp Physiol, May 1, 2006; 91(3): 511 - 519. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P O Collinson, D C Gaze, K Bainbridge, F Morris, B Morris, A Price, and S Goodacre Utility of admission cardiac troponin and "Ischemia Modified Albumin" measurements for rapid evaluation and rule out of suspected acute myocardial infarction in the emergency department. Emerg. Med. J., April 1, 2006; 23(4): 256 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Mitchell, M. D. Brown, I. B.A. Menown, and J. A. Kline Novel Protein Markers of Acute Coronary Syndrome Complications in Low-Risk Outpatients: A Systematic Review of Potential Use in the Emergency Department Clin. Chem., November 1, 2005; 51(11): 2005 - 2012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. van der Zee, H. J. Verberne, J. P. van Straalen, G. T.B. Sanders, B. L.F. Van Eck-Smit, R. J. de Winter, and J. C. Fischer Ischemia-Modified Albumin Measurements in Symptom-Limited Exercise Myocardial Perfusion Scintigraphy Reflect Serum Albumin Concentrations but Not Myocardial Ischemia Clin. Chem., September 1, 2005; 51(9): 1744 - 1746. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Worster, P.J. Devereaux, D. Heels-Ansdell, G. H. Guyatt, J. Opie, F. Mookadam, and S. A. Hill Capability of ischemia-modified albumin to predict serious cardiac outcomes in the short term among patients with potential acute coronary syndrome Can. Med. Assoc. J., June 21, 2005; 172(13): 1685 - 1690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. S. Apple, A. H.B. Wu, J. Mair, J. Ravkilde, M. Panteghini, J. Tate, F. Pagani, R. H. Christenson, M. Mockel, O. Danne, et al. Future Biomarkers for Detection of Ischemia and Risk Stratification in Acute Coronary Syndrome Clin. Chem., May 1, 2005; 51(5): 810 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Borderie, Y. Allanore, C. Meune, J. Y. Devaux, O. G. Ekindjian, and A. Kahan High Ischemia-Modified Albumin Concentration Reflects Oxidative Stress But Not Myocardial Involvement in Systemic Sclerosis Clin. Chem., November 1, 2004; 50(11): 2190 - 2193. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Panteghini Role and importance of biochemical markers in clinical cardiology Eur. Heart J., July 2, 2004; 25(14): 1187 - 1196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Zapico-Muniz, M. Santalo-Bel, J. Merce-Muntanola, J. A. Montiel, A. Martinez-Rubio, and J. Ordonez-Llanos Ischemia-Modified Albumin during Skeletal Muscle Ischemia Clin. Chem., June 1, 2004; 50(6): 1063 - 1065. [Full Text] [PDF]
|
|
|
|
|
|
B. Lumbreras-Lacarra, J. M. Ramos-Rincon, and I. Hernandez-Aguado Methodology in Diagnostic Laboratory Test Research in Clinical Chemistry and Clinical Chemistry and Laboratory Medicine Clin. Chem., March 1, 2004; 50(3): 530 - 536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M K Sinha, D Roy, D C Gaze, P O Collinson, and J-C Kaski Role of "Ischemia Modified Albumin", a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes Emerg. Med. J., January 1, 2004; 21(1): 29 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Sinha, D. C. Gaze, J. R. Tippins, P. O. Collinson, and J. C. Kaski Ischemia Modified Albumin Is a Sensitive Marker of Myocardial Ischemia After Percutaneous Coronary Intervention Circulation, May 20, 2003; 107(19): 2403 - 2405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Morrow, J. A. de Lemos, M. S. Sabatine, and E. M. Antman The Search for a Biomarker of Cardiac Ischemia Clin. Chem., April 1, 2003; 49(4): 537 - 539. [Full Text] [PDF]
|
|
|
|
|
|
N. V. Bhagavan, E. M. Lai, P. A. Rios, J. Yang, A. M. Ortega-Lopez, H. Shinoda, S. A.A. Honda, C. N. Rios, C. E. Sugiyama, and C.-E. Ha Evaluation of Human Serum Albumin Cobalt Binding Assay for the Assessment of Myocardial Ischemia and Myocardial Infarction Clin. Chem., April 1, 2003; 49(4): 581 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. S. Apple, H. E. Quist, A. P. Otto, W. E. Mathews, and M. M. Murakami Release Characteristics of Cardiac Biomarkers and Ischemia-modified Albumin as Measured by the Albumin Cobalt-binding Test after a Marathon Race Clin. Chem., July 1, 2002; 48(7): 1097 - 1100. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
